Changes in Hong Kong stocks | Goodwill B (02256) rose more than 6% to show the results of the pimitinib model-guided dose selection study

The Zhitong Finance App learned that Heyu-B (02256) rose more than 6%. As of press release, it had risen 6.82% to HK$3.6, with a turnover of HK$8.03 million.

According to the news, Heyu Pharmaceutical announced today that the company will announce a model-guided dose selection study of its self-developed novel oral, highly selective, and highly active CSF-1R small molecule inhibitor pimitinib to treat giant tendon sheath cytoma (TGCT) at the 2024 American Conference on Quantitative Pharmacology (ACoP). The ACoP conference will be held from November 10 to 13, 2024 in Phoenix, USA.

According to reports, pimitinib is a new oral, highly selective, and highly active CSF-1R small molecule inhibitor independently developed by Heyu Pharmaceutical. It has obtained breakthrough therapeutic drug and priority drug certification in China, the US, and Europe, as well as the US Fast Track certification and European orphan drug qualification for the treatment of inoperable giant cytomas of the tendon sheath.